Navigating Change: Insights into the US$185M ESR1 Mutated Metastatic Breast Cancer Diagnostics Market" "Unlocking Precision: ESR1 Mutated Metastatic Breast Cancer Diagnostics Reaches US$185 Million by 2033
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market had a market value of US$ 58.70 Million in 2022 and is expected to reach a market value of US$ 185 Million by 2023 to 2033, at a CAGR of 11%. The increasing prevalence of breast cancer and the growing need for personalised treatment options for patients with specific genetic mutations are driving the growth of the ESR1 mutated...
0 Σχόλια
0 Μοιράστηκε